Malaria vaccines: identifying Plasmodium falciparum liver-stage targets
The development of a highly efficacious and durable vaccine for malaria remains a top priority for global health researchers. Despite the huge rise in recognition of malaria as a global health problem and the concurrent rise in funding over the past 10–15 years, malaria continues to remain a widespr...
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Frontiers Media
2015
|
| _version_ | 1797093023031492608 |
|---|---|
| author | Longley, R Hill, A Spencer, A |
| author_facet | Longley, R Hill, A Spencer, A |
| author_sort | Longley, R |
| collection | OXFORD |
| description | The development of a highly efficacious and durable vaccine for malaria remains a top priority for global health researchers. Despite the huge rise in recognition of malaria as a global health problem and the concurrent rise in funding over the past 10–15 years, malaria continues to remain a widespread burden. The evidence of increasing resistance to anti-malarial drugs and insecticides is a growing concern. Hence, an efficacious and durable preventative vaccine for malaria is urgently needed. Vaccines are one of the most cost-effective tools and have successfully been used in the prevention and control of many diseases, however, the development of a vaccine for the Plasmodium parasite has proved difficult. Given the early success of whole sporozoite mosquito-bite delivered vaccination strategies, we know that a vaccine for malaria is an achievable goal, with sub-unit vaccines holding great promise as they are simple and cheap to both manufacture and deploy. However a major difficulty in development of sub-unit vaccines lies within choosing the appropriate antigenic target from the 5000 or so genes expressed by the parasite. Given the liver-stage of malaria represents a bottle-neck in the parasite’s life cycle, there is widespread agreement that a multi-component sub-unit malaria vaccine should preferably contain a liver-stage target. In this article we review progress in identifying and screening Plasmodium falciparum liver-stage targets for use in a malaria vaccine. |
| first_indexed | 2024-03-07T03:54:23Z |
| format | Journal article |
| id | oxford-uuid:c25c4c82-f387-4f83-9440-c261cd34a8cb |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:54:23Z |
| publishDate | 2015 |
| publisher | Frontiers Media |
| record_format | dspace |
| spelling | oxford-uuid:c25c4c82-f387-4f83-9440-c261cd34a8cb2022-03-27T06:08:25ZMalaria vaccines: identifying Plasmodium falciparum liver-stage targetsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:c25c4c82-f387-4f83-9440-c261cd34a8cbEnglishSymplectic Elements at OxfordFrontiers Media2015Longley, RHill, ASpencer, AThe development of a highly efficacious and durable vaccine for malaria remains a top priority for global health researchers. Despite the huge rise in recognition of malaria as a global health problem and the concurrent rise in funding over the past 10–15 years, malaria continues to remain a widespread burden. The evidence of increasing resistance to anti-malarial drugs and insecticides is a growing concern. Hence, an efficacious and durable preventative vaccine for malaria is urgently needed. Vaccines are one of the most cost-effective tools and have successfully been used in the prevention and control of many diseases, however, the development of a vaccine for the Plasmodium parasite has proved difficult. Given the early success of whole sporozoite mosquito-bite delivered vaccination strategies, we know that a vaccine for malaria is an achievable goal, with sub-unit vaccines holding great promise as they are simple and cheap to both manufacture and deploy. However a major difficulty in development of sub-unit vaccines lies within choosing the appropriate antigenic target from the 5000 or so genes expressed by the parasite. Given the liver-stage of malaria represents a bottle-neck in the parasite’s life cycle, there is widespread agreement that a multi-component sub-unit malaria vaccine should preferably contain a liver-stage target. In this article we review progress in identifying and screening Plasmodium falciparum liver-stage targets for use in a malaria vaccine. |
| spellingShingle | Longley, R Hill, A Spencer, A Malaria vaccines: identifying Plasmodium falciparum liver-stage targets |
| title | Malaria vaccines: identifying Plasmodium falciparum liver-stage targets |
| title_full | Malaria vaccines: identifying Plasmodium falciparum liver-stage targets |
| title_fullStr | Malaria vaccines: identifying Plasmodium falciparum liver-stage targets |
| title_full_unstemmed | Malaria vaccines: identifying Plasmodium falciparum liver-stage targets |
| title_short | Malaria vaccines: identifying Plasmodium falciparum liver-stage targets |
| title_sort | malaria vaccines identifying plasmodium falciparum liver stage targets |
| work_keys_str_mv | AT longleyr malariavaccinesidentifyingplasmodiumfalciparumliverstagetargets AT hilla malariavaccinesidentifyingplasmodiumfalciparumliverstagetargets AT spencera malariavaccinesidentifyingplasmodiumfalciparumliverstagetargets |